It is possible to manufacture monoclonal antibodies using traditional methods, but the challenges inherent in bispecific antibodies such as low titer, mismatched chains, unwanted fragments and higher aggregation levels require a heightened analytical focus on clonal cell selection. Here, Stuart Jamieson and Alice Harrison discuss high-throughput analytical strategies that enable right-first-time selection of the optimal clone to take through to clinical manufacture.
You may also be interested in:
Latest briefing from the Knowledge Center